<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nephropathol</journal-id><journal-id journal-id-type="iso-abbrev">J Nephropathol</journal-id><journal-id journal-id-type="publisher-id">J Nephropathol</journal-id><journal-id journal-id-type="pmc">J Nephropathol</journal-id><journal-id journal-id-type="publisher-id">JNP</journal-id><journal-title-group><journal-title>Journal of Nephropathology</journal-title></journal-title-group><issn pub-type="ppub">2251-8363</issn><issn pub-type="epub">2251-8819</issn><publisher><publisher-name>Society of Diabetic Nephropathy Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27047809</article-id><article-id pub-id-type="pmc">4790186</article-id><article-id pub-id-type="doi">10.15171/jnp.2016.07</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients; a randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zahed</surname><given-names>Narges-Sadat</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ghassami</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="A02">
<sup>2</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Nikbakht</surname><given-names>Hajar</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="A01"><sup>1</sup>Departement of Nephrology, Loghman Hakim Hospital, Shahid-Beheshti University of Medical Sciences, Tehran, Iran
</aff><aff id="A02"><sup>2</sup>Department of Internal Medicine, Loghman Hakim Hospital, Shahid-Beheshti University of Medical Sciences , Tehran, Iran
</aff><author-notes><corresp id="COR1"><label>*</label><italic>Corresponding author:</italic> Maryam Ghassami, Department of Internal Medicine, Division of Nephrology, Loghman-Hakim Hospital, Shahid-Beheshti University of Medical sciences, Tehran, Iran. <email>lcrdc.sbum@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>07</day><month>11</month><year>2015</year></pub-date><volume>5</volume><issue>1</issue><fpage>38</fpage><lpage>43</lpage><history><date date-type="received"><day>05</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>01</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2016 The Author(s)</copyright-statement><copyright-year>2016</copyright-year><license><license-p>
Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><self-uri xlink:href="http://nephropathol.com">http://nephropathol.com</self-uri><abstract><p>
<italic>Background:</italic> The most leading cause of death in end-stage renal disease (ESRD) patients are cardiovascular disease and inflammatory markers are related to coronary events. CO-Q10 (coenzyme Q10) is a protective supplement from free radical oxidative damage. In addition, hyperhomocysteinemia is an independent coronary artery disease (CAD) risk factor.
</p><p>
<italic>Objectives:</italic> Due to increasing oxidative stress in dialysis patients, and the effect of CO-Q10 in decrease oxidative stress, in this work, we assessed the effect of CO-Q10 on C-reactive protein (CRP) level as an inflammatory marker and homocysteine in dialysis patients.
</p><p>
<italic>Patients and Methods:</italic> This was a single-blind, randomized cross over clinical trial. Patients with ESRD were randomly allotted to two groups. All patients received placebo and C0- Q10 100mg/d during the three months in each stage, with two week washout period. Plasma level of CRP and homocysteine from the start of the work and at the conclusion of each menses, are evaluated.
</p><p>
<italic>Results:</italic> Thirty-four patients randomized, but 26 patients complete study protocol. The treatment effect of CO-Q10 on CRP level is significant (<italic>P</italic> &#x0003c; 0.001) (95% CI = -20.1 to -10.5) and it was also significant for the increasing albumin level. (<italic>P</italic> = 0.044) (95% CI = 0. 0-0.6), But there was not any substantial effect on serum homocysteine level (<italic>P</italic> = 0.630).
</p><p>
<italic>Conclusions:</italic> CO-Q10 could significantly decrease CRP level as an inflammatory marker and can protect cardiovascular events.
</p></abstract><kwd-group><kwd>Homocysteine</kwd><kwd>C-reactive protein</kwd><kwd>Renal insufficiency</kwd><kwd>Coenzyme Q10</kwd></kwd-group><counts><fig-count count="2"/><table-count count="4"/><ref-count count="25"/><page-count count="6"/></counts></article-meta><notes><p>
<italic>Please cite this paper as:</italic> Zahed NS, Ghassami M, Nikbakht H. Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients; a randomized clinical trial. J Nephropathol. 2016;5(1):38-43. DOI: 10.15171/jnp.2016.07
</p></notes></front><body><boxed-text position="float" id="bt1" orientation="portrait"><sec id="imp1"><title>Implication for health policy/practice/research/medical education:</title><p> The most leading cause of death in end-stage renal disease (ESRD) patients are cardiovascular disease and inflammatory markers are related to coronary events. Coenzyme Q10 (CO-Q10) is a protective supplement from free radical oxidative damage. In addition, hyperhomocysteinemia is an independent coronary artery disease (CAD) risk factor.Our study shows coenzyme Q10 reduced the C-reactive protein (CRP) as an inflammatory marker amongechronic renal failure patients.Inflammatory markers are supposed to result in many different complications. The authors hope, the results of the present study help to improve the complication of chronic renal failure patients patients.</p></sec></boxed-text><sec id="s1"><title>1. Background</title><p>
In patients with chronic kidney disease (CKD), one of the important comorbidities which may lead to mortality and morbidity is cardiovascular events (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>). Role of oxidative stress in coronary artery disease (CAD) is well established (<xref rid="R2" ref-type="bibr">2</xref>). On the other hand, in CKD patients other than traditional risk factors such as hyperlipidemia, other risk factors like oxidative stress and inflammation are attributed to elevated cardiovascular event rate (<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>). High levels of inflammatory markers like high-sensitivity C-reactive protein (hs-CRP) is able to predict risk of myocardial infarction (<xref rid="R5" ref-type="bibr">5</xref>). Elevated oxidant markers like hs-CRP are also detected in most of CKD patients as a sign of inflammation (<xref rid="R6" ref-type="bibr">6</xref>). Another detectable marker in inflammation and pathogenesis of CVD is homocysteine (<xref rid="R7" ref-type="bibr">7</xref>). Coenzyme Q10, is one of intracellular antioxidant components, protect cell membrane and mitochondrial protein from oxidative stress (<xref rid="R8" ref-type="bibr">8</xref>-<xref rid="R10" ref-type="bibr">10</xref>). Anti-oxidants like coenzyme Q10 is thought to reduce serum oxidant levels. While clinical trials studies, examined the effect of coenzyme Q10 in CVD patient (<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>), to our knowledge, there are few studies assessing the effect of coenzyme Q10 in CKD patients (<xref rid="R13" ref-type="bibr">13</xref>-<xref rid="R15" ref-type="bibr">15</xref>). In addition few recent studies look into the effect of coenzyme Q10 on inflammation and oxidative markers in CVD patients (<xref rid="R16" ref-type="bibr">16</xref>-<xref rid="R18" ref-type="bibr">18</xref>). Additionally, the possible relationship between coenzyme Q10 and oxidative stress markers in CKD patients was not been studies completely (<xref rid="R19" ref-type="bibr">19</xref>).
</p></sec><sec id="s2"><title>2. Objectives</title><p>
In the current study, we aimed to evaluate the effect coenzyme Q10 on some inflammatory markers including hs-CRP and homocysteine in patients with CKD.
</p></sec><sec id="s3"><title>3. Patients and Methods</title><p>
This is a single-blind, randomized cross over clinical trial. We studied 34 end-stage renal disease (ESRD) patients undergoing dialysis in Ashrafiesfehsni and Loghman-Hakim hospitals in Tehran from November 2013 to September 2014. From 373 patients referring to studied centers, 34 patients who fulfilled the inclusion criteria were enrolled. The inclusion criteria were acceptation to participate in the study, ESRD patients who were under dialysis for at least 8 months, blood pressure below 180/100 mm Hg, no smoking, patients whom, on folic acid therapy for at least 6 months before the study, absence of any active or chronic disease, hs-CRP more than 10 mg/L and finally highs level of homocysteine according to laboratory reference range prior to the study. Exclusion criteria were age under 18 years, cirrhosis, active neoplasm, post-menopausal women who are under hormone replacement therapy and hospitalization due to acute infection, acidosis or toxic shock. Before the clinical trial, age, level of blood pressure, Kt/V, level of hs-CRP and homocysteine were checked in all patients whom enrolled to the study. Thirty-four patients with hs-CRP &#x0003e;10 mg/L and high homocysteine level according to laboratory cut off were enrolled and divided into A and B groups by table of random numbers. Patients were not cognizant of their group allocation. Each patient should take one capsule a day as placebo or drug according to the randomization. In this study, group A was Q10-placebo and group B, regarded as placebo-Q10. During first three months of study patients in group A were administered CoQ10 (Health Burs Co) 100 mg once daily and patients in group B were administered placebo for 3 months. After 2 weeks of washout period patients in group A were administered placebo and in group B were administered CoQ10 for another 3 months with the same protocol. Quantitative measurement was applied to determine the hs-CRP levels and plasma homocysteine were measured using high-performance liquid chromatography (HPLC). Patients were closely observed by a physician during the study.
</p><sec id="s3-0-1"><title>
3.1. Ethical issues
</title><p>
1) All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards; 2) informed consent was obtained, they were free to leave the study at any time and; 3) research was approved by the ethical committee of Shahid-Beheshti University of Medical Sciences (Research proposal number: 297).
</p></sec><sec id="s3-0-2"><title>
3.2. Statistical analysis
</title><p>
Data are extracted as a mean &#x000b1;SD or as median values. <italic>T</italic> test, Fisher exact test and chi-square test was used to compare normally distributed continuous data and categorical information. Mann&#x02013;Whitney U test was applied to data that were not normally distributed. By Pocok method, carry over effect was examined. Linear mixed model (LMM) was applied to evaluate carry-over, period effect and treatment outcome. Period effect is the result of other treatments or the typical disease development during the study period. The treatment effect is the effect of intervention used in the study. The level of significance was <italic>P&#x02005;</italic>&#x0003c;&#x02005;0.05 for all compared variables. Data were analyzed using SPSS version 22 (SPSS Inc., Chicago, USA).
</p></sec></sec><sec id="s4"><title>4. Results</title><p>
Of 34 patients, 8 patients were not continued the study protocol. Two patients in group A died, one as the result of acute infection and the other patients by cardiovascular events. Six patients in group B (three due to hospitalization and three who died) were excluded from the study. Thus the study continued with 21 men and 13 adult females. There was not statistically difference between two groups of A and B according to gender, age, dialysis duration and Kt/V (<xref ref-type="table" rid="T1">Table 1</xref>). The etiologies of ESRD are described in <xref ref-type="table" rid="T2">Table 2</xref>. The average changes of parameters before and after intervention is shown in <xref ref-type="table" rid="T3">Table 3</xref>. There was not significant difference of systolic blood pressure (<italic>P</italic>&#x02005;=&#x02005;0.740) and hemoglobin (<italic>P</italic>&#x02005;=&#x02005;0.460) between two groups. In our study, after adjustments of statin impact, we found statistically significant carry-over effect for hs-CRP (P &#x0003c;0.001; <xref ref-type="fig" rid="F1">Figure 1</xref>). The results of the carry-over effect for homocysteine did not show a significant reduction in two periods of treatments (<italic>P</italic>&#x02005;=&#x02005;0.422). However period-effect was statically significant (<italic>P</italic>&#x02005;=&#x02005;0.009). Moreover, treatment effect for homocysteine was not significant (<italic>P</italic>&#x02005;=&#x02005;0.715). After adjustments of the effect of baseline characteristics and statin effect LMM the results for homocysteine was the same and the period effect on the serum homocysteine level was significant (<italic>P</italic>&#x02005;=&#x02005;0.001). The treatment effect (<italic>P</italic>&#x02005;=&#x02005;0.630) and carry-over effect was not of significant among the study groups (<italic>P</italic>&#x02005;=&#x02005;0.400). In this study, serum albumin was increased significantly according to treatment effect (<italic>P</italic>&#x02005;=&#x02005;0.04; CI 95% = 0. 0-0.6; <xref ref-type="fig" rid="F2">Figure 2</xref>). Additionally, the carry-over-effect and period effect were not significant (<xref ref-type="table" rid="T4">Table 4</xref>).
</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>
Patients&#x02019; baseline characteristics
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 0px 0px 1pt 0px ; border-style: none none solid none;background-color:#d2ac2a"><td rowspan="1" colspan="1">
<bold>Baseline characteristics</bold>
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
<bold>Total</bold>
</td><td rowspan="1" colspan="1">
<bold>Group A</bold>
</td><td rowspan="1" colspan="1">
<bold>Group B</bold>
</td><td rowspan="1" colspan="1">
<bold>P value</bold>
</td></tr><tr><td rowspan="1" colspan="1">Age(years)</td><td rowspan="1" colspan="1">
Mean&#x000b1;SD<break/>(range)
</td><td rowspan="1" colspan="1">
66.3&#x000b1;11.3<break/>(43-90)
</td><td rowspan="1" colspan="1">
66.4&#x000b1;11.5<break/>(43-90)
</td><td rowspan="1" colspan="1">
66.2&#x000b1;11.4<break/>(46-89)
</td><td rowspan="1" colspan="1">0.964</td></tr><tr style="background-color:#ffeea9"><td rowspan="2" colspan="1">Gender</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">21(61.8%)</td><td rowspan="1" colspan="1">11(64.7%)</td><td rowspan="1" colspan="1">10(58.8%)</td><td rowspan="1" colspan="1">0.724</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">13(38.2%)</td><td rowspan="1" colspan="1">6(35.3%)</td><td rowspan="1" colspan="1">7(41.2%)</td><td rowspan="1" colspan="1">
</td></tr><tr><td rowspan="1" colspan="1">Dialysis (weeks)</td><td rowspan="1" colspan="1">
Mean&#x000b1;SD<break/>(range)
</td><td rowspan="1" colspan="1">
47.2&#x000b1;40.2<break/>(8-180)
</td><td rowspan="1" colspan="1">
43.6&#x000b1;39.7<break/>(14-180)
</td><td rowspan="1" colspan="1">
52.7&#x000b1;42.2<break/>(8-156)
</td><td rowspan="1" colspan="1">0.611</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">Kt/V</td><td rowspan="1" colspan="1">
Mean&#x000b1;SD<break/>(range)
</td><td rowspan="1" colspan="1">
1.2&#x000b1;0.4<break/>(0.54-2.36)
</td><td rowspan="1" colspan="1">
1.22&#x000b1;0.48<break/>(0.54-2.36)
</td><td rowspan="1" colspan="1">
1.19&#x000b1;0.25<break/>(0.83-1.7)
</td><td rowspan="1" colspan="1">0.850</td></tr><tr><td rowspan="2" colspan="1">Statin supply</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">10(29.4%)</td><td rowspan="1" colspan="1">3(17.6%)</td><td rowspan="1" colspan="1">7(41.2%)</td><td rowspan="1" colspan="1">0.132</td></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">24(70.6%)</td><td rowspan="1" colspan="1">14(82.4%)</td><td rowspan="1" colspan="1">10(58.8%)</td><td rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>
The etiology of ESRD among study group
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 0px 0px 1pt 0px ; border-style: none none solid none;background-color:#d2ac2a"><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
<bold>Group A (Q10-placebo) n (%)</bold>
</td><td rowspan="1" colspan="1">
<bold>Group B (placebo-Q10) n (%)</bold>
</td><td rowspan="1" colspan="1">
<bold>P value</bold>
</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td rowspan="1" colspan="1">9 (52.9%)</td><td rowspan="1" colspan="1">5 (29.4%)</td><td rowspan="1" colspan="1">0.065</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">6 (35.3%)</td><td rowspan="1" colspan="1">3 (17.6%)</td><td rowspan="1" colspan="1">0.065</td></tr><tr><td rowspan="1" colspan="1">Idiopathic</td><td rowspan="1" colspan="1">2 (11.8%)</td><td rowspan="1" colspan="1">8 (47.1%)</td><td rowspan="1" colspan="1">0.065</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">Glomerulonephritis</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">1 (5.9%)</td><td rowspan="1" colspan="1">0.065</td></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>
Average of parameters before and after intervention
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 0px 0px 1pt 0px ; border-style: none none solid none;background-color:#d2ac2a"><td rowspan="1" colspan="1">
<bold>Parameters</bold>
</td><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
<bold>Week 0</bold>
</td><td rowspan="1" colspan="1">
<bold>First 3 months</bold>
</td><td rowspan="1" colspan="1">
<bold>Second 3 months</bold>
</td></tr><tr><td rowspan="2" colspan="1">Systolic blood pressure (mm Hg)</td><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">129&#x000b1;23</td><td rowspan="1" colspan="1">127&#x000b1;22</td><td rowspan="1" colspan="1">125&#x000b1;23</td></tr><tr><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">133&#x000b1;13</td><td rowspan="1" colspan="1">132&#x000b1;14</td><td rowspan="1" colspan="1">132&#x000b1;16</td></tr><tr style="background-color:#ffeea9"><td rowspan="2" colspan="1">Hemoglobin (g/dl)</td><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">10.76&#x000b1;1.6</td><td rowspan="1" colspan="1">10.49&#x000b1;1.76</td><td rowspan="1" colspan="1">11.11&#x000b1;2.11</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">10.31&#x000b1;1.11</td><td rowspan="1" colspan="1">10.3&#x000b1;0.87</td><td rowspan="1" colspan="1">10.3&#x000b1;1.26</td></tr><tr><td rowspan="2" colspan="1">hs-CRP (mg/dl)</td><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">24.6&#x000b1;11.7</td><td rowspan="1" colspan="1">8.3&#x000b1;7.2</td><td rowspan="1" colspan="1">16.9&#x000b1;15</td></tr><tr><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">34&#x000b1;15.6</td><td rowspan="1" colspan="1">23.6&#x000b1;3.2</td><td rowspan="1" colspan="1">28.1&#x000b1;21.1</td></tr><tr style="background-color:#ffeea9"><td rowspan="2" colspan="1">Homocysteine (&#x003bc;mol/l)</td><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">25.1&#x000b1;5.4</td><td rowspan="1" colspan="1">32&#x000b1;11.8</td><td rowspan="1" colspan="1">15.7&#x000b1;5.2</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">25.4&#x000b1;12.2</td><td rowspan="1" colspan="1">33.6&#x000b1;8.37</td><td rowspan="1" colspan="1">21.2&#x000b1;5.8</td></tr><tr><td rowspan="2" colspan="1">AST (IU/l)</td><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">15&#x000b1;7</td><td rowspan="1" colspan="1">20&#x000b1;7</td><td rowspan="1" colspan="1">18&#x000b1;6</td></tr><tr><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">22&#x000b1;6</td><td rowspan="1" colspan="1">24&#x000b1;7</td><td rowspan="1" colspan="1">28&#x000b1;9</td></tr><tr style="background-color:#ffeea9"><td rowspan="2" colspan="1">ALT (IU/l)</td><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">19&#x000b1;10</td><td rowspan="1" colspan="1">18&#x000b1;8</td><td rowspan="1" colspan="1">16&#x000b1;6</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">19&#x000b1;7</td><td rowspan="1" colspan="1">18&#x000b1;6</td><td rowspan="1" colspan="1">20&#x000b1;13</td></tr><tr><td rowspan="2" colspan="1">Albumin (g/dl)</td><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">3.87&#x000b1;0.58</td><td rowspan="1" colspan="1">3.93&#x000b1;0.54</td><td rowspan="1" colspan="1">3.77&#x000b1;0.34</td></tr><tr><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">3.41&#x000b1;0.27</td><td rowspan="1" colspan="1">3.56&#x000b1;0.37</td><td rowspan="1" colspan="1">3.59&#x000b1;0.38</td></tr></tbody></table></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>
Parameter analysis after Co-Q10 supplementation
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 0px 0px 1pt 0px ; border-style: none none solid none;background-color:#d2ac2a"><td rowspan="1" colspan="1">
</td><td rowspan="1" colspan="1">
<bold>Carry-over-effect</bold>
</td><td rowspan="1" colspan="1">
<bold>Period-effect</bold>
</td><td rowspan="1" colspan="1">
<bold>Treatment-effect</bold>
</td></tr><tr><td rowspan="1" colspan="1">Systolic blood pressure (mm Hg)</td><td rowspan="1" colspan="1">0.286</td><td rowspan="1" colspan="1">0.736</td><td rowspan="1" colspan="1">0.740</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td rowspan="1" colspan="1">0.793</td><td rowspan="1" colspan="1">0.453</td><td rowspan="1" colspan="1">0.460</td></tr><tr><td rowspan="1" colspan="1">CRP (g/dL)</td><td rowspan="1" colspan="1">0.013</td><td rowspan="1" colspan="1">0.063</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">Homocysteine (&#x003bc;mol/l)</td><td rowspan="1" colspan="1">0.659</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.630</td></tr><tr><td rowspan="1" colspan="1">AST (IU/l)</td><td rowspan="1" colspan="1">0.882</td><td rowspan="1" colspan="1">0.245</td><td rowspan="1" colspan="1">0.064</td></tr><tr style="background-color:#ffeea9"><td rowspan="1" colspan="1">ALT (IU/l)</td><td rowspan="1" colspan="1">0.215</td><td rowspan="1" colspan="1">0.860</td><td rowspan="1" colspan="1">0.157</td></tr><tr><td rowspan="1" colspan="1">Albumin (g/dl)</td><td rowspan="1" colspan="1">0.378</td><td rowspan="1" colspan="1">0.184</td><td rowspan="1" colspan="1">0.04</td></tr></tbody></table></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><graphic xlink:href="jnp-5-38-g001"/><statement><p>
Effect of Q10 on mean CRP levels. Q10 supply have statistically significant effect on the reduction of hs-CRP (<italic>P</italic>&#x02005;&#x0003c;&#x02005;0.001).
</p></statement></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><graphic xlink:href="jnp-5-38-g002"/><statement><p>
Effect of Q10 on mean serum albumin level. Serum albumin was significantly increased after treatment (<italic>P</italic> = 0.04).
</p></statement></fig></sec><sec id="s5"><title>5. Discussion</title><p>
Inflammation is highly associated with complications and cardiovascular adverse events in CKD. In the current study, we found coenzyme Q10 (100 mg/day) reduced serum hs-CRP levels as an inflammation marker. However homocysteine levels were not influenced by coenzyme Q10 supplementation. It should be noted that the period effect for homocysteine was significant. In our study blood pressure was not reduced significantly which was in accordance with the results of study by Mori et al (<xref rid="R20" ref-type="bibr">20</xref>). However Shargorodsky et al showed coenzyme Q10 could reduce blood pressure and increase elasticity in small and large vessels in non-CKD patients, with multiple cardiovascular risks (<xref rid="R21" ref-type="bibr">21</xref>). In 2013 another cross-over study suggested coenzyme Q10 did not have a favorable impact on diastolic heart function in hemodialysis patients (<xref rid="R22" ref-type="bibr">22</xref>). One clinical trial on CVD patients reported, coenzyme Q10 reduced IL-6 plasma levels and did not have coloration with hs-CRP and homocysteine (<xref rid="R17" ref-type="bibr">17</xref>). Lee et al in the other study suggested that coenzyme Q10 supplementation at the dose of 150 mg/day result in rapid and sustain a decrease in oxidative stress among CVD patients in comparison with healthy people (<xref rid="R18" ref-type="bibr">18</xref>). This effect on not healthy population may attribute to the highest levels of inflammatory markers in patient than in healthy people. In agreeing with Lee et al study, Gokbel et al shows coenzyme Q10 (100 mg/day) in healthy population did not affect the inflammatory markers (<xref rid="R19" ref-type="bibr">19</xref>). The above mentioned dose seems not to be sufficient to reduce inflammatory markers which were not elevated among healthy people. Although in dialysis patients, the serum oxidative markers is high (<xref rid="R23" ref-type="bibr">23</xref>), some other investigations could not obtain the favorable effect of coenzyme Q10 therapy on hs-CRP, homocysteine and IL6 (<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>). Among patients with breast cancer who were under treatment of coenzyme Q10 (100 mg/day) and vitamin B group (riboflavin 10 mg and niacin 50 mg), inflammatory markers included TNF-&#x003b1;, IL-8, IL-6, IL-1&#x003b2; were significantly decreased (<xref rid="R24" ref-type="bibr">24</xref>). Since all participants in our study used folic acid as a treatment of hyper homocysteinemia (<xref rid="R25" ref-type="bibr">25</xref>), period effect on homocysteine can be justified as folic acid effect. Furthermore albumin plasma levels as an effective factor for better surveillance of the patients, raised in our study.
</p></sec><sec id="s6"><title>6. Conclusions</title><p>
Co-Q10 supplement could reduce hs-CRP levels significantly, which is a known inflammatory factor. Co-Q10 could raise serum albumin level as a marker of better surveillance factor. According to the favorable effect of CoQ10 on Co-Q10 level, this antioxidant may play the role in reducing CVD events in CKD patients.
</p></sec><sec id="s7"><title>7. Limitations of the study</title><p>
The limitations of our study was small sample size and short duration of investigation. Due to confidence outcomes, more studies with larger sample size and in a longer period of time are recommended.
</p></sec><sec id="s8"><title>Acknowledgments</title><p>
We would like to acknowledge the clinical research development center of Loghman-Hakim hospital for its help.
</p></sec><sec id="s9"><title>Authors&#x02019; contribution</title><p>
NSZ designed the study and observed accuracy and validity of study protocol. MG collected the data and followed the studies objects. HN wrote the article and edited the manuscript.
</p></sec><sec id="s10"><title>Conflicts of interest</title><p>
The authors declared no competing interests.
</p></sec><sec id="s11"><title>Funding/Support</title><p>
None.
</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><name><surname>Hu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>YH</given-names></name><article-title>Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease</article-title><source>Med Sci Monit</source><year>2011</year><volume>17</volume><issue>6</issue><fpage>HY14</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">21629196</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><name><surname>Gosmanova</surname><given-names>EO</given-names></name><name><surname>Le</surname><given-names>NA</given-names></name><article-title>Cardiovascular complications in CKD patients: role of oxidative stress</article-title><source>Cardiol Res Pract</source><year>2011</year><volume>2011</volume><fpage>156326</fpage><pub-id pub-id-type="pmid">21253517</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><name><surname>Cachofeiro</surname><given-names>V</given-names></name><name><surname>Goicochea</surname><given-names>M</given-names></name><name><surname>de Vinuesa</surname><given-names>SG</given-names></name><name><surname>Oubi&#x000f1;a</surname><given-names>P</given-names></name><name><surname>Lahera</surname><given-names>V</given-names></name><name><surname>Lu&#x000f1;o</surname><given-names>J</given-names></name><article-title>Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease</article-title><source>Kidney Int</source><year>2008</year><volume>74</volume><fpage>S4</fpage><lpage>9</lpage></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><name><surname>Annuk</surname><given-names>M</given-names></name><name><surname>Zilmer</surname><given-names>M</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><name><surname>Linde</surname><given-names>T</given-names></name><name><surname>Fellstr&#x000f6;m</surname><given-names>B</given-names></name><article-title>Oxidative stress and endothelial function in chronic renal failure</article-title><source>J Am Soc Nephrol</source><year>2001</year><volume>12</volume><issue>12</issue><fpage>2747</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11729244</pub-id></element-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="other">
Libby P. The phatogenesis, prevention, and treatment of atherosclerosis. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, eds. Harrisons Principles of Internal Medicine.18th ed. New York: McGraw Hill; 2012:1983-92.
</mixed-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><name><surname>Descamps-Latscha</surname><given-names>B</given-names></name><name><surname>Witko-Sarsat</surname><given-names>V</given-names></name><name><surname>Nguyen-Khoa</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Gausson</surname><given-names>V</given-names></name><name><surname>Mothu</surname><given-names>N</given-names></name><etal/><article-title>Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabeticpredialysis patients</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>45</volume><issue>1</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15696442</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>JT</given-names></name><article-title>Circulating homocysteine is an inflammation marker and a risk factor of life-threatening inflammatory diseases</article-title><source>J Biomed Lab Sci</source><year>2007</year><volume>19</volume><issue>4</issue><fpage>107</fpage><lpage>11</lpage></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><name><surname>Ernster</surname><given-names>L</given-names></name><name><surname>Dallner</surname><given-names>G</given-names></name><article-title>Biochemical, physiological and medical aspects of ubiquinone function</article-title><source>Biochim Biophys Acta</source><year>1995</year><volume>1271</volume><issue>1</issue><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">7599208</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name><article-title>Coenzyme Q10 supplementation and heart failure</article-title><source>Nutr Rev</source><year>2007</year><volume>65</volume><issue>6</issue><fpage>286</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17605305</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Alleva</surname><given-names>R</given-names></name><name><surname>Tomasetti</surname><given-names>M</given-names></name><name><surname>Battino</surname><given-names>M</given-names></name><name><surname>Curatola</surname><given-names>G</given-names></name><name><surname>Littarru</surname><given-names>GP</given-names></name><name><surname>Folkers</surname><given-names>K</given-names></name><article-title>The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions</article-title><source>Proc Natl Acad Sci</source><year>1995</year><volume>92</volume><issue>20</issue><fpage>9388</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7568138</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Sarter</surname><given-names>B</given-names></name><article-title>Coenzyme Q10 and cardiovascular disease: a review</article-title><source>J Cardiovasc Nurs</source><year>2002</year><volume>16</volume><issue>4</issue><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12597259</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Shekelle</surname><given-names>P</given-names></name><name><surname>Morton</surname><given-names>S</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><article-title>Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease</article-title><source>Evid Rep Technol Assess (Summ)</source><year>2003</year><issue>83</issue><fpage>1</fpage><lpage>3</lpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Lippa</surname><given-names>S</given-names></name><name><surname>Colacicco</surname><given-names>L</given-names></name><name><surname>Calla</surname><given-names>C</given-names></name><name><surname>Sagliaschi</surname><given-names>G</given-names></name><name><surname>Angelitti</surname><given-names>AG</given-names></name><article-title>Coenzyme Q 10 levels, plasma lipids and peroxidation extent in renal failure and in hemodialytic patients</article-title><source>Mol Aspects Med</source><year>1994</year><volume>15</volume><fpage>s213</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7752833</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Lippa</surname><given-names>S</given-names></name><name><surname>Colacicco</surname><given-names>L</given-names></name><name><surname>Bondanini</surname><given-names>F</given-names></name><name><surname>Call&#x000e0;</surname><given-names>C</given-names></name><name><surname>Gozzo</surname><given-names>ML</given-names></name><name><surname>Ciccariello</surname><given-names>M</given-names></name><etal/><article-title>Plasma levels of coenzyme Q 10, vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications</article-title><source>Clin Chim Acta</source><year>2000</year><volume>292</volume><issue>1</issue><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">10686278</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Gazdikova</surname><given-names>K</given-names></name><name><surname>Gvozdjakova</surname><given-names>A</given-names></name><name><surname>Kucharska</surname><given-names>J</given-names></name><name><surname>Spustova</surname><given-names>V</given-names></name><name><surname>Braunova</surname><given-names>Z</given-names></name><name><surname>Dzurik</surname><given-names>R</given-names></name><article-title>oxidative stress and plasma concentrations of coenzyme Q10, &#x003b1;-Tocopherol, and &#x003b2;-Carotene in patients with a mild to moderate decrease of kidney function</article-title><source>Nephron</source><year>2001</year><volume>88</volume><issue>3</issue><fpage>285</fpage><pub-id pub-id-type="pmid">11423766</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><article-title>C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><issue>12</issue><fpage>836</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">10733371</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Lin</surname><given-names>PT</given-names></name><article-title>Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease</article-title><source>Nutrition</source><year>2012</year><volume>28</volume><issue>7</issue><fpage>767</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">22342390</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Tseng</surname><given-names>YF</given-names></name><name><surname>Yen</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>PT</given-names></name><article-title>Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial</article-title><source>Nutr J</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>142</fpage><pub-id pub-id-type="pmid">24192015</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Gokbel</surname><given-names>H</given-names></name><name><surname>Atalay</surname><given-names>H</given-names></name><name><surname>Okudan</surname><given-names>N</given-names></name><name><surname>Solak</surname><given-names>Y</given-names></name><name><surname>Belviranli</surname><given-names>M</given-names></name><name><surname>Turk</surname><given-names>S</given-names></name><article-title>Coenzyme Q10 and its relation with oxidant and antioxidant system markers in patients with end-stage renal disease</article-title><source>Ren Fail</source><year>2011</year><volume>33</volume><issue>7</issue><fpage>677</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">21787158</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Mori</surname><given-names>TA</given-names></name><name><surname>Burke</surname><given-names>V</given-names></name><name><surname>Puddey</surname><given-names>IB</given-names></name><name><surname>Irish</surname><given-names>AB</given-names></name><name><surname>Cowpland</surname><given-names>CA</given-names></name><name><surname>Beilin</surname><given-names>LJ</given-names></name><etal/><article-title>The effects of &#x003c9;3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial</article-title><source>JHypertens</source><year>2009</year><volume>27</volume><issue>9</issue><fpage>1863</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">19705518</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Shargorodsky</surname><given-names>M</given-names></name><name><surname>Debby</surname><given-names>O</given-names></name><name><surname>Matas</surname><given-names>Z</given-names></name><name><surname>Zimlichman</surname><given-names>R</given-names></name><article-title>Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors</article-title><source>Nutr Metab (Lond)</source><year>2010</year><volume>7</volume><fpage>55</fpage><pub-id pub-id-type="pmid">20604917</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Turk</surname><given-names>S</given-names></name><name><surname>Baki</surname><given-names>A</given-names></name><name><surname>Solak</surname><given-names>Y</given-names></name><name><surname>Kayrak</surname><given-names>M</given-names></name><name><surname>Atalay</surname><given-names>H</given-names></name><name><surname>Gaipov</surname><given-names>A</given-names></name><etal/><article-title>Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: A randomized double-blind placebo-controlled trial</article-title><source>Hemodial Int</source><year>2013</year><volume>17</volume><issue>3</issue><fpage>374</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">23360359</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Mehmetoglu</surname><given-names>I</given-names></name><name><surname>Yerlikaya</surname><given-names>FH</given-names></name><name><surname>Kurban</surname><given-names>S</given-names></name><name><surname>Erdem</surname><given-names>SS</given-names></name><name><surname>Tonbul</surname><given-names>Z</given-names></name><article-title>Oxidative stress markers in hemodialysis and peritoneal dialysis patients, including coenzyme Q10 and ischemia-modified albumin</article-title><source>Int J Artif Organs</source><year>2012</year><volume>35</volume><issue>3</issue><fpage>226</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">22461118</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Premkumar</surname><given-names>VG</given-names></name><name><surname>Yuvaraj</surname><given-names>S</given-names></name><name><surname>Vijayasarathy</surname><given-names>K</given-names></name><name><surname>Gangadaran</surname><given-names>SG</given-names></name><name><surname>Sachdanandam</surname><given-names>P</given-names></name><article-title>Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2007</year><volume>100</volume><issue>6</issue><fpage>387</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">17516992</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Bostom</surname><given-names>AG</given-names></name><name><surname>Carpenter</surname><given-names>MA</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Hunsicker</surname><given-names>L</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><etal/><article-title>Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients primary results from the folic acid for vascular outcome reduction in transplantation trial</article-title><source>Circulation</source><year>2011</year><volume>123</volume><issue>16</issue><fpage>1763</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">21482964</pub-id></element-citation></ref></ref-list></back></article>